Challenged by a pandemic, Harbig pursues a new approach to treating flu
When Anne Harbig found out she had won an award for her very first , she was shocked.

"It totally caught me by surprise," Harbig said. The paper was the culmination of all of her data from her Ph.D. research in Eva Böttcher-Friebertshäuser's lab at the Marburg Institute of Virology. "I always wanted to deepen my knowledge about viruses, and I was able to have this great Ph.D. project. I'm very grateful for my supervisor."
Harbig's research takes on the challenge of finding proteases that activate specific strains of influenza, which could be targeted with drugs in order to prevent infection and treat the disease. If inhibiting proteases proves effective in halting influenza infection, these methods could be used to target other enveloped viruses as well, including coronaviruses.
Harbig's project came with all kinds of challenges —wading through piles of transcriptome data, hundreds of in vitro studies with proteases that never activated, and now, the global COVID-19 pandemic that introduced all kinds of disruptions as she continues to pursue the project as a postdoc.
"Sometimes, especially on a Friday when you have the results of the week's experiments and things are not working and everything sucks," she said, "it's good to have the weekend to take a break and have ideas for how to do it differently next week."
To stop flu infection, target host enzymes
Anne Harbig seeks to develop targeted treatments that prevent influenza viruses from entering potential host cells. For a flu infection to begin, the virus must have its surface protein called hemagglutinin cleaved by host enzymes known as proteases.
"A protease is a protein, an enzyme, that cleaves other proteins at specific sites," Harbig explained.
Because the virus cannot enter a cell without a protease present, Harbig and her colleagues are identifying proteases involved in activating certain flu strains so they can develop drugs that can block them.
Harbig used RNA sequencing to search for any segments of mRNA coding for proteases found in the lower respiratory system of mice. Once she identified an array of lung proteases, each one was tested individually for its ability to split apart the hemagglutinin on the surface of influenza B viruses. The proteases that were able to do so were narrowed down further to four candidates that activated influenza B infection in mouse cells.
"The idea is, if we know the protease that activates our virus, we can use protease inhibitors to prevent infection," Harbig said. "If we know all the proteases involved, we can test the inhibitors in murine models, in vivo, and if they work there, then maybe later [we can test them] in human studies."
Harbig has earned her Ph.D. and is continuing to work on the project, hoping to see it reach human clinical trials.
Enjoy reading 91ÑÇÉ«´«Ã½ Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91ÑÇÉ«´«Ã½ Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles

Hidden strengths of an autistic scientist
Navigating the world of scientific research as an autistic scientist comes with unique challenges —microaggressions, communication hurdles and the constant pressure to conform to social norms, postbaccalaureate student Taylor Stolberg writes.

Richard Silverman to speak at 91ÑÇÉ«´«Ã½ 2025
Richard Silverman and Melissa Moore are the featured speakers at the 91ÑÇÉ«´«Ã½ annual meeting to be held April 12-15 in Chicago.

Women’s History Month: Educating and inspiring generations
Through early classroom experiences, undergraduate education and advanced research training, women leaders are shaping a more inclusive and supportive scientific community.

91ÑÇÉ«´«Ã½ honors Lawrence Tabak with public service award
He will deliver prerecorded remarks at the 2025 91ÑÇÉ«´«Ã½ Annual Meeting in Chicago.

91ÑÇÉ«´«Ã½ names 2025 JBC/Tabor Award winners
The six awardees are first authors of outstanding papers published in 2024 in the Journal of Biological Chemistry.

Daniel N. Hebert (1962–2024)
Daniel Hebert’s colleagues remember the passionate glycobiologistscientist, caring mentor and kind friend.